Filing Analysis
Securities Offering
Filed Mar 03, 2026
MEDIUM
VSee Health, Inc. stockholders approved a private placement proposal at a special meeting held on March 2, 2026. The approval allows for the issuance of up to 19,672,130 shares of common stock to certain warrant holders, satisfying Nasdaq Listing Rule 5635(d).
Red Flags
- Significant potential dilution: The approved issuance of 19,672,130 shares represents approximately 45.5% of the 43,244,355 shares outstanding as of the record date.
Key Facts
- Special Meeting of stockholders held on March 2, 2026.
- As of the February 2, 2026 record date, there were 43,244,355 shares of common stock outstanding.
- Stockholders approved the issuance of up to 19,672,130 shares of common stock to warrant holders.
- The Private Placement Proposal passed with 14,109,726 votes FOR and 7,698,963 votes AGAINST.
- The Adjournment Proposal was withdrawn as the primary proposal was successfully adopted.
Material Agreement
Filed Feb 19, 2026
MEDIUM
VSee Health disclosed two interrelated agreements with GoMyRx, Inc., a digital prescription fulfillment platform: a Managed Services Agreement (MSA) for cost-plus-10% services dated December 26, 2025, and a Stock Purchase Agreement dated January 16, 2026, under which VSEE will acquire 10% of GMRx for $2.0 million from Go Biz Holdings, LLC. The filing was made approximately 55 days after the earliest reported event, well beyond the standard 4-business-day 8-K deadline.
Red Flags
- Significantly late filing: earliest event December 26, 2025 but 8-K not filed until February 19, 2026 (~55 days), far exceeding the 4-business-day requirement
- $2.0 million equity investment in a private company with no disclosed financials for GMRx — shareholders cannot assess whether the implied $20M valuation is reasonable
- Secondary share purchase from Go Biz Holdings means the $2M capital goes to the selling entity, not to GMRx for growth — raises questions about who benefits
- Intertwined service and equity relationship: VSEE is simultaneously a service provider to and equity investor in GMRx, creating potential conflicts of interest
- GMRx can terminate the MSA with only 20 days notice, an asymmetrically unfavorable term for VSEE
- Restricted shares with no clear liquidity path — VSEE's $2M investment is effectively locked up in a private, illiquid position
- No disclosure of any relationship between Go Biz Holdings and VSEE insiders or directors — the filing is silent on whether this is a related-party transaction
Key Facts
- VSEE entered a Managed Services Agreement with GoMyRx, Inc. on December 26, 2025, to provide platform administration, customer/user support, vendor coordination, and reporting/governance services
- MSA billing is at actual cost plus 10% margin, invoiced monthly — a modest markup
- MSA expires December 26, 2027 with optional 6-month extensions; GMRx can terminate with only 20 days written notice
- On January 16, 2026, VSEE agreed to purchase $2.0 million of GMRx common stock from Go Biz Holdings, LLC, representing 10% ownership in GMRx (implying a $20M valuation for GMRx)
- Shares purchased are restricted securities under Section 4(a)(2) / Rule 506 of Regulation D — cannot be freely sold
- GoMyRx is described as 'an affiliate company of the GoMyDocs healthcare ecosystem'
- The $2M purchase is a secondary transaction (from Go Biz Holdings), meaning proceeds go to the seller, not to GMRx for business operations
- Filing signed by Co-CEO Imoigele Aisiku on February 19, 2026 — 55 days after the December 26 MSA event
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.